RS49629B - Farmaceutska formulacija omeprazola - Google Patents

Farmaceutska formulacija omeprazola

Info

Publication number
RS49629B
RS49629B YUP-608/99A YU60899A RS49629B RS 49629 B RS49629 B RS 49629B YU 60899 A YU60899 A YU 60899A RS 49629 B RS49629 B RS 49629B
Authority
RS
Serbia
Prior art keywords
omeprazole
determined
cloud point
hpmc
solution
Prior art date
Application number
YUP-608/99A
Other languages
English (en)
Inventor
Magnus Erickson
Lars Josefsson
Original Assignee
Astra Aktiebolaget,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407122&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS49629(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Aktiebolaget, filed Critical Astra Aktiebolaget,
Publication of YU60899A publication Critical patent/YU60899A/sh
Publication of RS49629B publication Critical patent/RS49629B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Oralna farmaceutska formulacija sa entero prevlakom koja sadrži kao aktivnu supstancu jedinjenje izabrano iz grupe omeprazola, alkalne soli omeprazola, (-) enantiomera omeprazola i alkalne soli (-) enantniomera operazola, u kojoj formulacija sadrži z rnasti materijal od aktivne supstance i opciono jedinjenja koje alkalno reaguje, a aktivna supstanca je u smeši sa jednim ili više farmaceutski prihvatljivih ekscipijenata kao što su sredstva za vezivanje, punioci i/ili sredstva za dezintegraciju, i na pomenutom zrnastom materijalu je sloj za razdvajanje i prevlaka od entero sloja, naznačena time, što je sredstvo za vezivanje i/ili sastojak sloja za razdvajanje hidroksipropil metilceluloza (HPMC) niske viskoznosti sa tačkom zamućenja najmanje 45.6°C određenom kao temperatura na kojoj je transmisija svetlosti specifičnog sistema 96%, i gde je tačka zamućenja određena rastvaranjem HPMC u koncentraciji od 1.2% u smeši 0.235 M rastvora fosfatnog pufera i simulirane želudačne tečnosti pH 1.2 u odnosu 4:5 pri pH rastvora između 6.75 i 6.85, ili što je sredstvo za vezivanje i/ili sastojak sloja za razdvajanje, HPMC niske viskoznosti sa tačkom zamućenja najmanje 44.5°C određenom kao temperatura na kojoj je transmisija svetlosti specifičnog sistema 95% i gde je tačka zamućenja određena rastvaranjem HPMC niske viskoznosti u koncentraciji od 1.0% u 0.235 M rastvoru smeše fosfatnog pufera i simulirane želudačne tečnosti pH 1.2 u odnosu 4:5 pri pH rastvora između 6.75 i 6.85. Prijava sadrži još 17 zahteva.
YUP-608/99A 1997-05-28 1998-05-18 Farmaceutska formulacija omeprazola RS49629B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702000A SE9702000D0 (sv) 1997-05-28 1997-05-28 New pharmaceutical formulation

Publications (2)

Publication Number Publication Date
YU60899A YU60899A (sh) 2002-06-19
RS49629B true RS49629B (sr) 2007-08-03

Family

ID=20407122

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-608/99A RS49629B (sr) 1997-05-28 1998-05-18 Farmaceutska formulacija omeprazola

Country Status (41)

Country Link
US (1) US6090827A (sr)
EP (1) EP0984773B1 (sr)
JP (1) JP4649001B2 (sr)
KR (1) KR100540721B1 (sr)
CN (1) CN1123338C (sr)
AR (1) AR012698A1 (sr)
AT (1) ATE234078T1 (sr)
AU (1) AU722879B2 (sr)
BR (1) BR9809484A (sr)
CA (1) CA2290531C (sr)
CZ (1) CZ298972B6 (sr)
DE (1) DE69812089T2 (sr)
DK (1) DK0984773T3 (sr)
DZ (1) DZ2494A1 (sr)
EE (1) EE03903B1 (sr)
EG (1) EG24044A (sr)
ES (1) ES2195342T3 (sr)
HK (1) HK1025744A1 (sr)
HR (1) HRP980260B1 (sr)
HU (1) HU229154B1 (sr)
ID (1) ID24654A (sr)
IL (1) IL132895A0 (sr)
IS (1) IS2856B (sr)
MA (1) MA26497A1 (sr)
MY (1) MY122298A (sr)
NO (1) NO328100B1 (sr)
NZ (1) NZ500886A (sr)
PL (1) PL194634B1 (sr)
PT (1) PT984773E (sr)
RS (1) RS49629B (sr)
RU (1) RU2207121C2 (sr)
SA (1) SA98190304B1 (sr)
SE (1) SE9702000D0 (sr)
SI (1) SI0984773T1 (sr)
SK (1) SK286625B6 (sr)
TN (1) TNSN98068A1 (sr)
TR (1) TR199902890T2 (sr)
TW (1) TW575435B (sr)
UA (1) UA71541C2 (sr)
WO (1) WO1998053803A1 (sr)
ZA (1) ZA984178B (sr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US20020039597A1 (en) * 1998-04-20 2002-04-04 Koji Ukai Stabilized compositions containing benzimidazole-type compounds
SE9803772D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
SE9902386D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
JP4081273B2 (ja) 1999-10-20 2008-04-23 エーザイ・アール・アンド・ディー・マネジメント株式会社 ベンズイミダゾール系化合物安定化方法
US20040092511A1 (en) * 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
JP2002234842A (ja) * 2001-02-09 2002-08-23 Kyowa Yakuhin Kogyo Kk 内服腸溶性製剤
JP2005521662A (ja) * 2002-01-25 2005-07-21 サンタラス インコーポレイティッド プロトンポンプ阻害剤の経粘膜送達
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
FR2843121B3 (fr) 2002-08-02 2004-09-10 Rhodia Chimie Sa Agent ignifugeant, procede de preparation et l'utilisation de cet agent
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040146558A1 (en) * 2003-01-28 2004-07-29 Kyowa Pharmaceutical Co., Ltd. Oral enteric-coated preparation
JP4567340B2 (ja) * 2003-01-29 2010-10-20 武田薬品工業株式会社 被覆製剤の製造方法
CA2514539C (en) 2003-01-29 2012-03-06 Takeda Pharmaceutical Company Limited Process for producing coated preparation
ZA200506397B (en) * 2003-01-29 2006-11-29 Takeda Pharmaceutical Process for producing coated preparation
WO2004073654A2 (en) * 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained supression of gastric acid
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
CN1311824C (zh) * 2004-04-21 2007-04-25 常州市第四制药厂有限公司 奥美拉唑肠溶微粒制剂及制备方法
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1747800B1 (en) * 2005-07-29 2009-03-18 Rottapharm S.p.A. Combination of itriglumide and proton pump inhibitors in the treatment of gastrointestinal and related disorders
JP2009538901A (ja) * 2006-06-01 2009-11-12 デクセル ファーマ テクノロジーズ エルティーディー． 複式ユニット製薬的製剤
KR101436516B1 (ko) * 2007-07-23 2014-09-02 주식회사태평양제약 코팅된 펠렛을 함유하는 현탁정 및 이의 제조방법
CA2704132A1 (en) * 2007-09-28 2009-04-02 Ctc Bio, Inc. Pharmaceutical composition containing esomeprazole
CA2720800C (en) * 2008-03-28 2013-07-30 Ferrer Internacional S.A. Capsule for the prevention of cardiovascular diseases
MX2011001341A (es) 2008-08-19 2011-03-29 Xenoport Inc Prodrogas de metil hidrogeno fumarato, sus composiciones farmaceuticas, y metodos de uso.
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
JP2015526476A (ja) 2012-08-22 2015-09-10 ゼノポート，インコーポレイティド メチル水素フマレートの経口剤形およびそのプロドラッグ
CN102961356A (zh) * 2012-12-11 2013-03-13 山西云鹏制药有限公司 一种含奥美拉唑的蓝色肠溶片剂的制备方法
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
JP2016534133A (ja) 2013-09-06 2016-11-04 ゼノポート，インコーポレイティド （ｎ，ｎ−ジエチルカルバモイル）メチル メチル（２ｅ）ブト−２−エン−１，４−ジオエートの結晶形態、その合成方法及び使用
WO2015042294A1 (en) * 2013-09-18 2015-03-26 Xenoport, Inc. Nanoparticle compositions of dimethyl fumarate
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US20230058473A1 (en) 2020-01-27 2023-02-23 Towa Pharmaceutical Co., Ltd. Esomeprazole oral preparation and method for producing the same
KR102432084B1 (ko) 2021-11-16 2022-08-12 알리코제약(주) S-오메프라졸을 함유하는 안정성이 개선되고 소형화된 정제
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
JPH05255088A (ja) * 1991-11-05 1993-10-05 Yoshitomi Pharmaceut Ind Ltd 抗潰瘍剤含有製剤
JP2669446B2 (ja) * 1992-03-23 1997-10-27 信越化学工業株式会社 医薬品コーティング液用原料粉粒体
JPH0733659A (ja) * 1992-07-17 1995-02-03 Yoshitomi Pharmaceut Ind Ltd 抗潰瘍剤含有製剤
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
BR9506018A (pt) * 1994-07-08 1997-09-02 Astra Ab Forma farmacêutica oral de múltipla dosagem unitária em tablete processos para a preparação da mesma para a inibição da secreção de ácido gástrico em mamiferos e no homem e para o tratamento das doenças inflamatórias gastrointestinais em mamiferos e no homem e embalagem de ampola de pressão transversal
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms

Also Published As

Publication number Publication date
SK159099A3 (en) 2000-06-12
HK1025744A1 (en) 2000-11-24
PL337237A1 (en) 2000-08-14
SI0984773T1 (en) 2003-10-31
UA71541C2 (uk) 2004-12-15
JP4649001B2 (ja) 2011-03-09
AU722879B2 (en) 2000-08-10
CA2290531A1 (en) 1998-12-03
EE9900540A (et) 2000-06-15
IS5245A (is) 1999-11-11
CN1258217A (zh) 2000-06-28
IL132895A0 (en) 2001-03-19
US6090827A (en) 2000-07-18
ES2195342T3 (es) 2003-12-01
TNSN98068A1 (fr) 2005-03-15
RU2207121C2 (ru) 2003-06-27
NO328100B1 (no) 2009-12-07
ID24654A (id) 2000-07-27
TR199902890T2 (xx) 2000-02-21
HU229154B1 (en) 2013-09-30
DK0984773T3 (da) 2003-07-07
HRP980260B1 (en) 2003-10-31
NO995809L (no) 2000-01-28
ATE234078T1 (de) 2003-03-15
PT984773E (pt) 2003-07-31
PL194634B1 (pl) 2007-06-29
KR100540721B1 (ko) 2006-01-10
DE69812089T2 (de) 2004-03-04
HUP0002182A3 (en) 2003-02-28
MA26497A1 (fr) 2004-12-20
CZ420299A3 (cs) 2000-05-17
CN1123338C (zh) 2003-10-08
EP0984773B1 (en) 2003-03-12
ZA984178B (en) 1998-11-30
AR012698A1 (es) 2000-11-08
KR20010013104A (ko) 2001-02-26
NO995809D0 (no) 1999-11-26
EP0984773A1 (en) 2000-03-15
HRP980260A2 (en) 1999-02-28
EG24044A (en) 2008-04-13
DZ2494A1 (fr) 2003-01-25
DE69812089D1 (de) 2003-04-17
WO1998053803A1 (en) 1998-12-03
CZ298972B6 (cs) 2008-03-26
IS2856B (is) 2013-11-15
AU7680398A (en) 1998-12-30
BR9809484A (pt) 2000-06-20
MY122298A (en) 2006-04-29
HUP0002182A2 (hu) 2002-05-29
SA98190304B1 (ar) 2006-10-11
EE03903B1 (et) 2002-12-16
YU60899A (sh) 2002-06-19
NZ500886A (en) 2001-11-30
JP2002500665A (ja) 2002-01-08
SK286625B6 (sk) 2009-02-05
SE9702000D0 (sv) 1997-05-28
CA2290531C (en) 2006-12-12
TW575435B (en) 2004-02-11

Similar Documents

Publication Publication Date Title
RS49629B (sr) Farmaceutska formulacija omeprazola
NO175240C (no) Fremgangsmåte for fremstilling av et langsomt frigivende farmasöytisk preparat som omfatter sekundære granuler
BR0013720A (pt) Formulação em pelota de liberação controlada
DE69909316D1 (de) Pharmazeutische formulierung mit omeprazol
NO20023313L (no) Nye substituerte benzimidazol doseringsformer og fremgangsmåte for anvendelse av samme
DE69636724D1 (de) Drei verschiedene polymertypen enthaltende formulierung mit verzögerter freigabe
RU99126869A (ru) Фармацевтический препарат омепразола
SE9502244D0 (sv) A composition and a process for the preparation thereof
YU46421B (sh) Postupak za dobijanje farmaceutskog preparata kiselinski labilnih supstanci za oralnu upotrebu
ATE291912T1 (de) Fenofibrat enthaltende pharmazeutische zusammensetzung und verfahren zu ihrer herstellung
RS52706B (sr) Formiranje osušene rekonstituisane vezikule za farmaceutsku primenu
YU42399A (sh) Farmaceutska smeša rastvorljiva u vodi u jonskom kompleksu
DK164259C (da) Farmaceutisk formulering til langsom frigivelse af den aktive bestanddel og fremgangsmaade til fremstilling af en saadan formulering
RS54699B1 (sr) Višečestične formulacije pantoprazola
DK0868912T3 (da) Anvendelse af redispergerbare polymerpulvere eller polymergranulater til coating af farmaceutiske eller agrokemiske applikationsformer
DK0801559T3 (da) Fremgangsmåde til fremstilling af orale doseringsformer indeholdende et beta-lactam antibiotikum
KR900005964A (ko) 분산성 제형
RS55392B1 (sr) Brzo topljiva formulacija za oralno doziranje
FR2778848B1 (fr) Forme pharmaceutique multiparticulaire a liberation programmee et pulsee et son procede de preparation
DK1461017T3 (da) Farmaceutisk sammensætning til styret frigivelse af et beta-lactam-antibiotikum
ES2056122T3 (es) Un proceso para la fabricacion de pequeñas esferas gastrorresistentes y enterosolubles de enzima soluble y un preparado farmaceutico asi obtenido.
YU49109B (sh) Postupak za izradu čestičastih sastava
DE69416034D1 (de) Pharmazeutische Zubereitung zur rektalen Verabreichung von pharmakologisch wirksamen Verbindungen
KR880008809A (ko) 안정화된 중아황산염 메나디온 제제 및 이들의 제조
TH51654A (th) สูตรผสมทางเภสัชกรรมโอมีพราโซล